Meningitis Clinical Trial
Official title:
Single Centre Open-Label Randomised Trial of Meningococcal Serogroup ACYW-135 B Cell Response to Primary & Booster Doses of ACWY Conjugate Vaccine & Primary Dose of ACWY Polysaccharide With Booster Dose of ACWY Conjugate in Adults
The purpose of the study is to evaluate and compare the immune response to two vaccines
against 4 related bacteria: meningococcal serogroups A, C, W−135 and Y. These bacteria can
cause meningitis and /or septicaemia (blood poisoning). The two vaccines are a
protein−polysaccharide conjugate vaccine (MenACWY)and a meningococcal plain polysaccharide
vaccine(MenACWY PS). Both vaccines are licensed and are currently used for travellers to
areas with a high incidence of invasive meningococcal disease. However, plain polysaccharide
vaccines are known to be poorly immunogenic in children and they do not stimulate
immunological memory, apart from the serogroup A component. In contrast, a
protein-polysaccharide conjugate vaccine against meningococcal serogroups A, C, W−135 and Y
has been found to be immunogenic in infants and to be able to induce immunological memory.
The proposed study is a single centre, open−label, randomised, controlled study in 150
healthy adults aged 18−70 years. The participants will be given either 2 injections of the
meningococcal protein−polysaccharide conjugate vaccine one month apart, or one injection of
the meningococcal plain polysaccharide vaccine followed one month later with an injection of
the meningococcal conjugate vaccine. Blood samples will be collected before immunisation and
at several time points following immunisations to evaluate the level of meningococcal
specific antibody induced by two different vaccination regimes. The data derived from the
study will be relevant in determining which of these vaccines should be used in preference
in travellers who are receiving immunisation against meningococcal disease before travelling
to high risk areas. Additionally, a number of scientific questions regarding the nature of
the immune response to the two vaccines (specifically looking at the white blood cells
responsible for producing antibodies, known as B cells) and the role of genetic variations
in influencing the vaccine recipient's immune response will be addressed in the study.
Status | Completed |
Enrollment | 150 |
Est. completion date | October 2010 |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Participant is willing and able to give informed consent for participation after the nature of the study has been explained - Male or Female, aged 18- 70 years inclusive - In good health as determined by: - Medical history - History-directed physical examination - Clinical judgment of the investigator - Female participants of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter - Able (in the Investigator's opinion) and willing to comply with all study requirements - Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study Exclusion Criteria: - Are unwilling or unable to give written informed consent to participate in the study - Have previously received any meningococcal vaccine (this will be confirmed with the participant's general practitioner after enrolment) - Have previously been diagnosed with laboratory confirmed meningococcal disease - Have a history of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component - Have a known or suspected autoimmune disease or impairment /alteration of immune function resulting from (for example): - Receipt of any immunosuppressive therapy - Congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months or long-term systemic corticosteroid therapy* (*prednisolone or equivalent for more than two consecutive weeks within the past 3 months). - Have a suspected or known HIV infection or HIV related disease - Have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 3 months - Have a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time - Have any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives - Participation in another clinical trial investigating a vaccine, a drug, a medical device, or a medical procedure - Pregnancy as confirmed by a positive pregnancy test - Currently breast-feeding |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United Kingdom | University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine | Oxford |
Lead Sponsor | Collaborator |
---|---|
University of Oxford | Novartis Vaccines |
United Kingdom,
Ramasamy MN, Clutterbuck EA, Haworth K, Bowman J, Omar O, Thompson AJ, Blanchard-Rohner G, Yu LM, Snape MD, Pollard AJ. Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom. Clin Vaccine Immunol. 2014 Aug;21(8):1164-8. doi: 10.1128/CVI.00099-14. Epub 2014 Jun 25. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint will be whether the SBA GMT at day 7 following MenACWY is = 30% greater than that observed at day 7 following MenACWY PS. | Day 7 | No | |
Secondary | The measurement of meningococcal serogroup C SBAs (using human complement) at day 7 following the initial immunisation with MenACWY and MenACWY PS. | Day 7 | No | |
Secondary | The measurement of meningococcal serogroup A and C specific SBAs (using human complement) at day 28 following the initial immunisation with MenACWY and MenACWY PS, and at day 7 and day 28 following the 'follow up' immunisation with MenACWY. | Day 7-28 | No | |
Secondary | Meningococcal serogroup W-135 and Y SBAs will also be performed on a subset of samples obtained at the above timepoints. | Day 7-28 | No | |
Secondary | The measurement of meningococcal serogroup A, C, W-135 and Y specific memory B cells and plasma B cells at day 7, and memory B cells at day 28 after first immunisation with MenACWY and MenACWY PS, and after the 'follow up' immunisation with MenACWY. | Day 7-56 | No | |
Secondary | Other assessments of the immune response to MenACWY and MenACWY PS (e.g. measurement of meningococcal serogroup A, C, W-135 and Y specific IgG by ELISA) may also be performed. | Day 7-56 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03445416 -
Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men
|
N/A | |
Completed |
NCT02526394 -
Pertussis and Meningitis C Concomitant Vaccination in Adolescents
|
Phase 4 | |
Completed |
NCT01442675 -
Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine
|
Phase 2 | |
Completed |
NCT00539032 -
Immunology and Safety of Menactra® in Children in Saudi Arabia
|
Phase 3 | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Recruiting |
NCT05496673 -
Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda
|
N/A | |
Completed |
NCT02003495 -
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
|
Phase 3 | |
Recruiting |
NCT00901602 -
Lebanese Interhospital Pneumococcal Surveillance Program
|
||
Completed |
NCT00850603 -
Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®
|
Phase 4 | |
Completed |
NCT02591290 -
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects
|
Phase 4 | |
Completed |
NCT03112031 -
Treatment With Tamoxifen in Cryptococcal Meningitis
|
Phase 2 | |
Completed |
NCT02881957 -
Hypovitaminosis D in Neurocritical Patients
|
Phase 2/Phase 3 | |
Completed |
NCT06334796 -
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
|
Early Phase 1 | |
Completed |
NCT03378258 -
Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
|
||
Recruiting |
NCT05637645 -
Different Approaches of Spinal Anesthesia in Patients Undergoing Cesarean Section
|
N/A | |
Completed |
NCT02841254 -
Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies
|
N/A | |
Completed |
NCT02003313 -
Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
|
Phase 3 | |
Recruiting |
NCT01619462 -
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
|
Phase 3 | |
Completed |
NCT01239043 -
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
|
Phase 2 | |
Completed |
NCT00495690 -
Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease
|
Phase 3 |